Several brokerages have updated their recommendations and price targets on shares of Teva Pharmaceutical Industries Limited (NYSE: TEVA) in the last few weeks:

  • 10/6/2017 – Teva Pharmaceutical Industries Limited was given a new $23.00 price target on by analysts at Piper Jaffray Companies. They now have a “hold” rating on the stock.
  • 10/5/2017 – Teva Pharmaceutical Industries Limited had its “market perform” rating reaffirmed by analysts at Wells Fargo & Company.
  • 10/5/2017 – Teva Pharmaceutical Industries Limited was given a new $15.00 price target on by analysts at Morgan Stanley. They now have an “underweight” rating on the stock.
  • 10/4/2017 – Teva Pharmaceutical Industries Limited was given a new $20.00 price target on by analysts at Wells Fargo & Company. They now have a “hold” rating on the stock.
  • 10/4/2017 – Teva Pharmaceutical Industries Limited had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $24.00 price target on the stock.
  • 10/4/2017 – Teva Pharmaceutical Industries Limited was given a new $21.00 price target on by analysts at Barclays PLC. They now have an “equal weight” rating on the stock.
  • 10/4/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Mizuho. They now have a $16.00 price target on the stock.
  • 10/4/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 10/4/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at Zacks Investment Research from a “strong sell” rating to a “hold” rating. According to Zacks, “Pricing erosion in the U.S. generics business and the continued deterioration in Venezuela is hurting sales at Teva which led to a guidance and dividend cut in August. Teva is facing several other challenges in the form of generic competition for Copaxone, new competition for branded products and a high cost base and debt load. Also, Teva’s shares underperformed the generic industry this year so far. Nonetheless, Teva is progressing with its branded/generics drugs pipeline and is looking to strengthen its biosimilar pipeline. The Actavis Generics acquisition is contributing to growth of the Generics unit. Meanwhile, Teva is focusing on cost cutting and divestments to boost growth. However, a clear path to growth is not visible. Estimates have declined ahead of the company’s Q3 earnings release. The company also has a negative record of earnings surprises in recent quarters.”
  • 10/4/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Maxim Group. They wrote, “Shares of TEVA are under pressure in the wake of the FDA’s approval of Mylan’s ANDA for generic copaxone 3x/week & 20 mg/ml QD injection. Teva has a press release estimating the impact of the two launches to its 4Q earnings of at least $0.25. Our estimates are under review but our Hold remaining remains in-effect. We had anticipated generic copaxone (3x) but not until 2018.””
  • 10/4/2017 – Teva Pharmaceutical Industries Limited had its “market perform” rating reaffirmed by analysts at Cowen and Company. They now have a $18.00 price target on the stock, down previously from $30.00.
  • 10/2/2017 – Teva Pharmaceutical Industries Limited was given a new $17.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 10/2/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 9/28/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 9/21/2017 – Teva Pharmaceutical Industries Limited had its price target lowered by analysts at Sanford C. Bernstein from $28.00 to $20.00. They now have a “market perform” rating on the stock.
  • 9/21/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 9/18/2017 – Teva Pharmaceutical Industries Limited had its price target lowered by analysts at Royal Bank Of Canada from $21.00 to $15.00. They now have an “underperform” rating on the stock.
  • 9/18/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $17.00 price target on the stock.
  • 9/14/2017 – Teva Pharmaceutical Industries Limited had its “neutral” rating reaffirmed by analysts at UBS AG. They now have a $19.00 price target on the stock.
  • 9/14/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Maxim Group. They now have a $15.50 price target on the stock.
  • 9/13/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 9/13/2017 – Teva Pharmaceutical Industries Limited had its “buy” rating reaffirmed by analysts at Gabelli.
  • 9/12/2017 – Teva Pharmaceutical Industries Limited had its price target lowered by analysts at Jefferies Group LLC from $21.00 to $18.50. They now have a “hold” rating on the stock.
  • 9/11/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
  • 9/11/2017 – Teva Pharmaceutical Industries Limited was upgraded by analysts at BTIG Research from a “neutral” rating to a “buy” rating. They now have a $24.00 price target on the stock.
  • 9/11/2017 – Teva Pharmaceutical Industries Limited was given a new $17.00 price target on by analysts at Cantor Fitzgerald. They now have a “hold” rating on the stock.
  • 9/6/2017 – Teva Pharmaceutical Industries Limited had its price target raised by analysts at JMP Securities from $13.00 to $14.00. They now have an “underperform” rating on the stock.
  • 9/5/2017 – Teva Pharmaceutical Industries Limited had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $27.00 price target on the stock.
  • 9/5/2017 – Teva Pharmaceutical Industries Limited had its “underperform” rating reaffirmed by analysts at Royal Bank Of Canada.
  • 9/1/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 8/31/2017 – Teva Pharmaceutical Industries Limited had its “neutral” rating reaffirmed by analysts at Goldman Sachs Group, Inc. (The). They now have a $21.00 price target on the stock, down previously from $28.00.
  • 8/30/2017 – Teva Pharmaceutical Industries Limited had its “hold” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $27.00 price target on the stock.
  • 8/25/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at TheStreet from a “c-” rating to a “d+” rating.
  • 8/23/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at Credit Suisse Group from a “neutral” rating to an “underperform” rating. They now have a $13.00 price target on the stock, down previously from $25.00.
  • 8/22/2017 – Teva Pharmaceutical Industries Limited had its “neutral” rating reaffirmed by analysts at Mizuho. They now have a $16.00 price target on the stock, down previously from $30.00.
  • 8/16/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at Citigroup Inc. from a “buy” rating to a “neutral” rating. They now have a $19.00 price target on the stock, down previously from $32.00.
  • 8/16/2017 – Teva Pharmaceutical Industries Limited was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded up 0.76% during mid-day trading on Tuesday, reaching $15.89. The company had a trading volume of 12,372,607 shares. The firm’s 50 day moving average price is $16.87 and its 200-day moving average price is $26.56. The company’s market capitalization is $16.14 billion. Teva Pharmaceutical Industries Limited has a 12 month low of $15.22 and a 12 month high of $45.14.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its quarterly earnings data on Thursday, August 3rd. The company reported $0.99 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). The company had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The firm’s revenue was up 12.9% on a year-over-year basis. During the same period in the prior year, the company earned $1.25 earnings per share. Equities research analysts anticipate that Teva Pharmaceutical Industries Limited will post $4.26 earnings per share for the current year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, September 14th. Shareholders of record on Tuesday, August 29th were paid a dividend of $0.085 per share. This represents a $0.34 annualized dividend and a yield of 2.14%. The ex-dividend date of this dividend was Friday, August 25th. Teva Pharmaceutical Industries Limited’s dividend payout ratio is presently -15.36%.

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.